Unicycive Therapeutics (UNCY) Preferred Stock Liabilities (2023 - 2024)
Unicycive Therapeutics' (UNCY) quarterly Preferred Stock Liabilities came in at $46.2 million in Q2 2024, up 76.27% YoY from $26.2 million in Q3 2023, and little changed on a QoQ basis from $46.2 million in Q1 2024.
Unicycive Therapeutics (UNCY) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Unicycive Therapeutics (UNCY) has 2 years of Preferred Stock Liabilities data on file, last reported at $46.2 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 46.19 Mn |
| Mar 31, 2024 | 46.19 Mn |
| Jun 30, 2023 | 26.20 Mn |